"KORIGROUP, Affiliate of Hanmi Pharm, Nears Completion of Breast Milk Oligosaccharide Substitute Development"

Commercialization of the 'Human Milk Oligosaccharides (HMO)' product, an immune component found in breast milk developed by Cori Group, a Hanmi Pharmaceutical Group affiliate established by Lim Jong-yoon, president of Hanmi Pharmaceutical, is imminent.

On the 23rd, Cori Group announced that it has developed an HMO that can replace the function of HMO without artificial elements at the Cori Italy AAT Microbiome Research Institute and is preparing for commercialization. The production and sales of this product, researched and developed (R&D) by Cori Group, will be handled by Dx&Vx, a subsidiary of Cori Group.

Human breast milk is rich in immune-related components such as HMO, proteins, and lipids. The World Health Organization (WHO) also states that "breast milk supply is very important within the first six months after birth" and recommends that "appropriate complementary foods continue to be supplied until the age of two." The market size for such HMO products is expected to grow from 280 billion KRW in 2022 to 1.5 trillion KRW by 2030.

Han Sung-joon, CTO of Dx&Vx, said, “Some multinational companies have developed artificial HMO products using genetic modification technologies, but due to ▲high production costs ▲low yield ▲limited scale-up of production facilities ▲biological rejection caused by artificial manufacturing processes ▲safety issues from new by-products, alternatives are needed. The development of an HMO substitute by Cori Group that excludes artificial elements not only supplies products necessary for the health of babies and mothers but also aligns with the social goal of promoting infant health in an era of low birth rates.”

This content was produced with the assistance of AI translation services.